Summary: Gallidermin
Pfam includes annotations and additional family information from a range of different sources. These sources can be accessed via the tabs below.
This is the Wikipedia entry entitled "Lantibiotics". More...
Lantibiotics Edit Wikipedia article
| Gallidermin | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| Symbol | Gallidermin | ||||||||
| Pfam | PF02052 | ||||||||
| InterPro | IPR006079 | ||||||||
| SCOP | 1g5q | ||||||||
| SUPERFAMILY | 1g5q | ||||||||
| TCDB | 1.C.20 | ||||||||
| OPM superfamily | 170 | ||||||||
| OPM protein | 1mqy | ||||||||
|
|||||||||
Lantibiotics are a class of peptide antibiotics that contain the characteristic polycyclic thioether amino acids lanthionine or methyllanthionine, as well as the unsaturated amino acids dehydroalanine and 2-aminoisobutyric acid.
Lanthionine is composed of two alanine residues that are crosslinked on their β-carbon atoms by a thioether (monosulphide) linkage.
Lantibiotics are produced by a large number of Gram-positive bacteria such as Streptococcus and Streptomyces to attack other Gram-positive bacteria, and as such, they are considered a member of the bacteriocins. Bacteriocins are classified according to their extent of posttranslational modification. The lantibiotics are a class of more extensively modified bacteriocins, also called Class I bacteriocins. (Bacteriocins for which disulfide bonds are the only modification to the peptide are Class II bacteriocins.)
Lantibiotics are well studied because of the commercial use of these bacteria in the food industry for making dairy products such as cheese.
Nisin and epidermin are members of a family of lantibiotics that bind to a cell wall precursor lipid component of target bacteria and disrupt cell wall production. The duramycin family of lantibiotics binds phosphoethanolamine in the membranes of its target cells and seem to disrupt several physiological functions.
Contents |
[edit] History
The name lantibiotics was introduced in 1988 as an abbreviation for "lanthionine-containing peptide antibiotics".[1] The first structures of these antimicrobial agents were produced by pioneering work by Gross and Morell in the late 1960s and early 1970s, thus marking the formal introduction of lantibiotics. Since then, lantibiotics such as nisin have been used auspiciously for food preservation and have yet to encounter significant bacterial resistance. These attributes of lantibiotics have led to more detailed research into their structures and biosynthetic pathways.
[edit] Classification
- Type A lantibiotics are long flexible molecules - e.g. nisin, bisin, subtilin, epidermin, gallidermin[2] Subgroup AI includes mutacin II; subgroup AII includes mutacin I and III.
- Type B lantibiotics are globular - e.g. mersacidin.[3][4] actagardine, duramycin, and cinnamycin.[5]
Some contain 2 peptides, eg haloduracin.[6]
[edit] Examples
| Lantibiotic | Type | Nr of residues |
Nr of thioether links |
Other links |
refs |
|---|---|---|---|---|---|
| nisin subtilin |
A | 34 | 5 | 0 | |
| gallidermin epidermin |
A | 21 | 3 | 1 | [2] |
| mersacidin | B | 20 | 4 | [3] | |
| actagardine | B | 19 | 4 | 0 | |
| cinnamycin duramycin |
B | 19 | 3 | 1 | [5] |
| Sublancin 168 | ? | 37 | 1 | 2 | [7] |
| Plantaricin C | B | 27 | 4 | 0 |
(Sublancin may be an S-linked glycopeptide.[8]
[edit] Biosynthesis
They are synthesised with a leader polypeptide sequence which is only removed during the transport of the molecule out of the synthesising cell. They are synthesized by ribosomes, which distinguishes them from most natural antibiotics, which are synthesized by specialised enzymes.[9]
[edit] Mechanism of action
Lantibiotics show substantial specificity for some components (e.g. lipid II) of bacterial cell membranes especially of Gram-positive bacteria. Type A lantibiotics kill rapidly by pore formation, type B lantibiotics inhibit peptidoglycan biosynthesis.[10] for discussion of mechanism of action. They are active in very low concentrations.[11]
[edit] Application
[edit] Food preservation
Lantibiotics are produced by Gram-positive bacteria and show strong antimicrobial action towards a wide range of other Gram-positive bacteria.[12] As such they have become attractive candidates for use in food preservation (by inhibiting pathogens that cause food spoilage) and the pharmaceutical industry (to prevent or fight infections in humans or animals).[12]
[edit] Veterinary antibiotic
Duramycin is used for chickens.
[edit] Clinical antibiotic
One type B lantibiotic NVB302 entered phase 1 clinical trials in 2011 for use against Clostridium difficile,[13] and reported good results in 2012.[14]
[edit] Database
BACTIBASE is an open-access database for bacteriocins including lantibiotics.[15][16]
[edit] References
- ^ Chatterjee C, Paul M, Xie L, van der Donk WA (February 2005). "Biosynthesis and mode of action of lantibiotics". Chem. Rev. 105 (2): 633–84. doi:10.1021/cr030105v. PMID 15700960.
- ^ a b Kellner R, Jung G, Hörner T, Zähner H, Schnell N, Entian KD, Götz F (October 1988). "Gallidermin: a new lanthionine-containing polypeptide antibiotic". Eur. J. Biochem. 177 (1): 53–9. doi:10.1111/j.1432-1033.1988.tb14344.x. PMID 3181159.
- ^ a b Sass P, Jansen A, Szekat C, Sass V, Sahl HG, Bierbaum G (2008). "The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus". BMC Microbiol. 8: 186. doi:10.1186/1471-2180-8-186. PMC 2592248. PMID 18947397.
- ^ Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG (March 1995). "Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?". Antimicrob. Agents Chemother. 39 (3): 714–9. doi:10.1128/AAC.39.3.714. PMC 162610. PMID 7793878.
- ^ a b Makino A, Baba T, Fujimoto K, Iwamoto K, Yano Y, Terada N, Ohno S, Sato SB, Ohta A, Umeda M, Matsuzaki K, Kobayashi T (January 2003). "Cinnamycin (Ro 09-0198) promotes cell binding and toxicity by inducing transbilayer lipid movement". J. Biol. Chem. 278 (5): 3204–9. doi:10.1074/jbc.M210347200. PMID 12446685.
- ^ Cooper LE, McClerren AL, Chary A, van der Donk WA (October 2008). "Structure-activity relationship studies of the two-component lantibiotic haloduracin". Chem. Biol. 15 (10): 1035–45. doi:10.1016/j.chembiol.2008.07.020. PMC 2633096. PMID 18940665.
- ^ Stein T (May 2005). "Bacillus subtilis antibiotics: structures, syntheses and specific functions". Mol. Microbiol. 56 (4): 845–57. doi:10.1111/j.1365-2958.2005.04587.x. PMID 15853875.
- ^ Oman TJ, Boettcher JM, Wang H, Okalibe XN, van der Donk WA (February 2011). "Sublancin is not a lantibiotic but an S-linked glycopeptide". Nat. Chem. Biol. 7 (2): 78–80. doi:10.1038/nchembio.509. PMC 3060661. PMID 21196935.
- ^ Siegers K, Heinzmann S, Entian KD (May 1996). "Biosynthesis of lantibiotic nisin. Posttranslational modification of its prepeptide occurs at a multimeric membrane-associated lanthionine synthetase complex". J. Biol. Chem. 271 (21): 12294–301. PMID 8647829.
- ^ Brötz H and Sahl H-G. (2000.). "New insights into the mechanism of action of lantibiotics—diverse biological effects by binding to the same molecular target". Journal of Antimicrobial Chemotherapy 46 (1): 1–6. doi:10.1093/jac/46.1.1. PMID 10882681.
- ^ Cotter, Hill, Ross (2005). Bacterial Lantibiotics: Strategies to Improve Therapeutic Potential 6. Current Protein and Peptide Science. pp. 61–75.
- ^ a b van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP (October 1999). "Lantibiotics: biosynthesis, mode of action and applications". Nat Prod Rep 16 (5): 575–87. doi:10.1039/a804531c. PMID 10584332.
- ^ "New antibiotic compound enters phase I clinical trial". Press Release. Wellcome Trust. 2011-11-03.
- ^ Parker S (2012-08-06). "Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers". Press Release. Celtic Pharma Holding.
- ^ Hammami R, Zouhir A, Ben Hamida J, Fliss I (2007). "BACTIBASE: a new web-accessible database for bacteriocin characterization". BMC Microbiology 7: 89. doi:10.1186/1471-2180-7-89. PMC 2211298. PMID 17941971.
- ^ Hammami R, Zouhir A, Le Lay C, Ben Hamida J, Fliss I (2010). "BACTIBASE second release: a database and tool platform for bacteriocin characterization". BMC Microbiology 10: 22. doi:10.1186/1471-2180-10-22. PMC 2824694. PMID 20105292.
[edit] Further reading
- Jack R, Bierbaum G, Heidrich C, Sahl HG (September 1995). "The genetics of lantibiotic biosynthesis". Bioessays 17 (9): 793–802. doi:10.1002/bies.950170909. PMID 8763832.
- Sahl HG, Jack RW, Bierbaum G (June 1995). "Biosynthesis and biological activities of lantibiotics with unique post-translational modifications". Eur. J. Biochem. 230 (3): 827–53. doi:10.1111/j.1432-1033.1995.0827g.x. PMID 7601145.
- Sahl HG, Bierbaum G (1998). "Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria". Annu. Rev. Microbiol. 52: 41–79. doi:10.1146/annurev.micro.52.1.41. PMID 9891793.
- Stein T (May 2005). "Bacillus subtilis antibiotics: structures, syntheses and specific functions". Mol. Microbiol. 56 (4): 845–57. doi:10.1111/j.1365-2958.2005.04587.x. PMID 15853875.
- Smith JL (2002). Structural and functional characterization of the lantibiotic mutacin (Ph.D.). University of Florida. http://etd.fcla.edu/UF/UFE1001183/smith_jl.pdf.
[edit] External links
- "Complete list of lantibiotics". BACTIBASE Database. Functional Proteomics & Alimentary Bio-preservation Research Unit at Institute of Applied Biological Sciences Tunis (ISSBAT), Tunisia.
This page is based on a Wikipedia article. The text is available under the Creative Commons Attribution/Share-Alike License.
This tab holds the annotation information that is stored in the Pfam database. As we move to using Wikipedia as our main source of annotation, the contents of this tab will be gradually replaced by the Wikipedia tab.
Gallidermin Provide feedback
No Pfam abstract.
External database links
| PANDIT: | PF02052 |
| PRINTS: | PR00323 |
| Pseudofam: | PF02052 |
| SCOP: | 1g5q |
| SYSTERS: | Gallidermin |
This tab holds annotation information from the InterPro database.
InterPro entry IPR006079
Lantibiotics are heavily-modified bacteriocin-like peptides from Gram- positive bacteria. They contain alpha,beta-unsaturated amino acids (dehydroalanine and dehydrobutyrine) and lanthionine or 3-methyllanthionine rings (collectively known as thioether rings). There are 2 types of lantibiotic:
- Type A (which include nisin, subtilin, epidermin, gallidermin and Pep5) are strongly cationic and bactericidal - nisin, subtilin and Pep5 inhibit the growth of Gram-positive bacteria, probably by voltage-dependent pore formation in the cytoplasmic membrane, resulting in cellular efflux of electrolytes, amino acids and ATP;
- Type B lantibiotics possess at most one positive charge and are not bactericidal.
This family contains both type A and type B molecules.
Gene Ontology
The mapping between Pfam and Gene Ontology is provided by InterPro. If you use this data please cite InterPro.
| Biological process | defense response to Gram-positive bacterium (GO:0050830) |
Domain organisation
Below is a listing of the unique domain organisations or architectures in which this domain is found. More...
Loading domain graphics...
Alignments
We store a range of different sequence alignments for families. As well as the seed alignment from which the family is built, we provide the full alignment, generated by searching the sequence database using the family HMM. We also generate alignments using four representative proteomes (RP) sets, the NCBI sequence database, and our metagenomics sequence database. More...
View options
We make a range of alignments for each Pfam-A family. You can see a description of each above. You can view these alignments in various ways but please note that some types of alignment are never generated while others may not be available for all families, most commonly because the alignments are too large to handle.
| Seed (3) |
Full (129) |
Representative proteomes | NCBI (51) |
Meta (1) |
||||
|---|---|---|---|---|---|---|---|---|
| RP15 (1) |
RP35 (2) |
RP55 (2) |
RP75 (5) |
|||||
| Jalview | ||||||||
| HTML | ||||||||
| PP/heatmap | 1 | |||||||
| Pfam viewer | ||||||||
1Cannot generate PP/Heatmap alignments for seeds; no PP data available
Key:
available,
not generated,
— not available.
Format an alignment
Download options
We make all of our alignments available in Stockholm format. You can download them here as raw, plain text files or as gzip-compressed files.
| Seed (3) |
Full (129) |
Representative proteomes | NCBI (51) |
Meta (1) |
||||
|---|---|---|---|---|---|---|---|---|
| RP15 (1) |
RP35 (2) |
RP55 (2) |
RP75 (5) |
|||||
| Raw Stockholm | ||||||||
| Gzipped | ||||||||
You can also download a FASTA format file containing the full-length sequences for all sequences in the full alignment.
External links
MyHits provides a collection of tools to handle multiple sequence alignments. For example, one can refine a seed alignment (sequence addition or removal, re-alignment or manual edition) and then search databases for remote homologs using HMMER3.
HMM logo
HMM logos is one way of visualising profile HMMs. Logos provide a quick overview of the properties of an HMM in a graphical form. You can see a more detailed description of HMM logos and find out how you can interpret them here. More...
Trees
This page displays the phylogenetic tree for this family's seed alignment. We use FastTree to calculate neighbour join trees with a local bootstrap based on 100 resamples (shown next to the tree nodes). FastTree calculates approximately-maximum-likelihood phylogenetic trees from our seed alignment.
Note: You can also download the data file for the tree.
Curation and family details
This section shows the detailed information about the Pfam family. You can see the definitions of many of the terms in this section in the glossary and a fuller explanation of the scoring system that we use in the scores section of the help pages.
Curation
| Seed source: | IPR001049 |
| Previous IDs: | none |
| Type: | Family |
| Author: | Mian N, Bateman A |
| Number in seed: | 3 |
| Number in full: | 129 |
| Average length of the domain: | 45.90 aa |
| Average identity of full alignment: | 56 % |
| Average coverage of the sequence by the domain: | 90.42 % |
HMM information
| HMM build commands: |
build method: hmmbuild -o /dev/null HMM SEED
search method: hmmsearch -Z 23193494 -E 1000 --cpu 4 HMM pfamseq
|
||||||||||||
| Model details: |
|
||||||||||||
| Model length: | 52 | ||||||||||||
| Family (HMM) version: | 10 | ||||||||||||
| Download: | download the raw HMM for this family |
Species distribution
Sunburst controls
ShowThis visualisation provides a simple graphical representation of the distribution of this family across species. You can find the original interactive tree in the adjacent tab. More...
Tree controls
HideThe tree shows the occurrence of this domain across different species. More...
Loading...
Please note: for large trees this can take some time. While the tree is loading, you can safely switch away from this tab but if you browse away from the family page entirely, the tree will not be loaded.
Structures
For those sequences which have a structure in the Protein DataBank, we use the mapping between UniProt, PDB and Pfam coordinate systems from the PDBe group, to allow us to map Pfam domains onto UniProt sequences and three-dimensional protein structures. The table below shows the structures on which the Gallidermin domain has been found. There are 1 instances of this domain found in the PDB. Note that there may be multiple copies of the domain in a single PDB structure, since many structures contain multiple copies of the same protein seqence.
Loading structure mapping...

Archea
Eukaryota
Bacteria
Other sequences
Viruses
Unclassified
Viroids
Unclassified sequence